Strongbridge Starts Another Phase 3 Trial of Its Cushing’s Therapy
Strongbridge Biopharma has begun dosing patients in another Phase 3 clinical trial of its Cushing’s syndrome therapy Recorlev (levoketoconazole). The company will enroll roughly 35 patients in the LOGICS (NCT03277690). Those participating in another Phase 3 trial, SONICS (NCT01838551), can enter the LOGICS study as well. LOGICS “marks an…